StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 3.1 %

Shares of NYSE BTX opened at $1.79 on Friday. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10. The firm has a fifty day moving average of $2.15 and a 200-day moving average of $1.80. The stock has a market capitalization of $105.29 million, a PE ratio of -0.79 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.